Kala Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for diseases with significant unmet medical need. The company's primary focus is on ophthalmology, with a proprietary mucus-penetrating particles (MPP) technology platform. Kala's lead products include treatments for dry eye disease and other ocular conditions. The company went public in 2017 and has established partnerships with major pharmaceutical companies.
Kala Pharmaceuticals has received investment from 1 venture capital firm.
A biopharmaceutical company focused on developing and commercializing therapies for rare and underserved diseases, particularly in ophthalmology.
Kala Pharmaceuticals has received investment from GreatPoint Ventures. These venture capital firms and investors provide both capital and strategic support.
Kala Pharmaceuticals was founded in 2009 and is headquartered in Watertown, MA.
Kala Pharmaceuticals operates in the Biotech sector. A biopharmaceutical company focused on developing and commercializing therapies for rare and underserved diseases, particularly in ophthalmology.
